首页> 外文期刊>Veterinary Microbiology >Vaccination with recombinant 4 x M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens
【24h】

Vaccination with recombinant 4 x M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens

机译:重组4 x M2e.HSP70c融合蛋白作为通用候选疫苗的疫苗接种可增强体液和细胞介导的免疫反应,并减少针对鸡的H9N2流感实验性攻击的病毒脱落

获取原文
获取原文并翻译 | 示例
           

摘要

As cellular immunity is essential for virus clearance, it is commonly accepted that no adequate cellular immunity is achieved by all available inactivated HA-based influenza vaccines. Thus, an improved influenza vaccine to induce both humoral and cell-mediated immune responses is urgently required to control LPAI H9N2 outbreaks in poultry farms. M2e-based vaccines have been suggested and developed as a new generation of universal vaccine candidate against influenza A infection. Our previous study have shown that a prime-boost administration of recombinant 4 x M2e.HSP70c (r4M2e/H70c) fusion protein compared to conventional HA-based influenza vaccines provided full protection against lethal dose of influenza A viruses in mice. In the present study, the immunogenicity and protective efficacy of (r4M2e/H70c) was examined in chickens. The data reported herein show that protection against H9N2 viral challenge was significantly increased in chickens by injection of r4M2e/H70c compared with injection of conventional HA-based influenza vaccine adjuvanted with MF59 or recombinant 4 x M2e (r4M2e) without HSP70c. Oropharyngeal and cloacal shedding of the virus was detected in all of the r4M2e/H70c vaccinated birds at 2 days after challenge, but the titer was low and decreased rapidly to reach undetectable levels at 7 days after challenge. Moreover, comparison of protective efficacy against LPAI H9N2 in birds intramuscularly immunized with r4M2e/H70c likely represented the ability of the M2e-based vaccine in providing cross-protection against heterosubtypic H9N2 challenge and also allowed the host immune system to induce HA-homosubtype neutralizing antibody against H9N2 challenge. This protective immunity might be attributed to enhanced cell-mediated immunity, which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type (IFN-gamma) and Th2-type (IL-4) cytokines production and increased CD4(+) to CD8(+) ratios, resulting from the injection of four tandem repeats of the ectodomain of the conserved influenza matrix protein M2 (4 x M2e) genetically fused to C-terminus of Mycobacterium tuberculosis HSP70 (mHSP70c). (C) 2014 Elsevier B.V. All rights reserved.
机译:由于细胞免疫对于清除病毒至关重要,因此,人们普遍认为,所有可用的灭活基于HA的流感疫苗都无法获得足够的细胞免疫。因此,迫切需要一种改进的流感疫苗来诱导体液和细胞介导的免疫反应,以控制家禽农场中的LPAI H9N2爆发。已经提出并开发了基于M2e的疫苗,作为针对A型流感感染的新一代通用疫苗候选物。我们以前的研究表明,与传统的基于HA的流感疫苗相比,重组4 x M2e.HSP70c(r4M2e / H70c)融合蛋白的初免加强给药可提供针对小鼠致命A型流感病毒的全面保护。在本研究中,(r4M2e / H70c)的免疫原性和保护功效在鸡中进行了检查。本文报道的数据表明,与注射常规佐以MF59或不含HSP70c的重组4 x M2e(r4M2e)的传统HA型流感疫苗相比,注射r4M2e / H70c可显着提高鸡对H9N2病毒攻击的保护能力。在攻击后第2天,在所有r4M2e / H70c疫苗接种的禽类中都检测到了口咽和泄殖腔的病毒脱落,但是在攻击后第7天,滴度很低,并且迅速下降至无法检测的水平。此外,在用r4M2e / H70c肌肉注射的禽类中对LPAI H9N2的保护功效的比较可能代表了基于M2e的疫苗提供针对异型H9N2攻击的交叉保护的能力,并且还允许宿主免疫系统诱导HA-同源亚型中和抗体。对抗H9N2挑战。这种保护性免疫可能归因于增强的细胞介导免疫,这被解释为淋巴细胞增殖增加,Th1-型(IFN-γ)和Th2-型(IL-4)细胞因子产生水平增加以及CD4(+)的增加。 CD8(+)比率,是通过注射四个保守重复的保守流感基质蛋白M2(4 x M2e)胞外域的串联重复序列而得来的,该M2e基因与结核分枝杆菌HSP70(mHSP70c)的C端基因融合。 (C)2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号